Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
pmid: | ||||
pmid:3360596 | ||||
pmid:9870780 | ||||
Pastores SM et al. | Posttraumatic multiple-organ dysfunction syndrome: role of mediators in systemic inflammation and subsequent organ failure. | 1996 | Acad Emerg Med | pmid:8727633 |
Goldring WP and Pattenden G | The phomactins. A novel group of terpenoid platelet activating factor antagonists related biogenetically to the taxanes. | 2006 | Acc. Chem. Res. | pmid:16700534 |
Yamada T et al. | Effects of inhaled nitric oxide on platelet-activating factor-induced pulmonary hypertension in dogs. | 1998 | Acta Anaesthesiol Scand | pmid:9542566 |
Nathan N et al. | Variations in blood platelet-activating-factor levels after protamine reversal of heparin in humans. | 1992 | Acta Anaesthesiol Scand | pmid:1574976 |
Sipka S et al. | Atropine is an inhibitor of the chemiluminescence induced by platelet-activating factor in human neutrophils. | 1987 | Acta Biochim. Biophys. Hung. | pmid:3132002 |
Ren J et al. | Protective effect of dexmedetomidine against myocardial ischemia-reperfusion injury in rabbits. | 2018 | Acta Cir Bras | pmid:29412230 |
Peterson JR et al. | Platelet activating factor antagonist design. 3. X-ray crystal structure and intermolecular crystal lattice interactions of methyl trans-4-acetoxymethyl-4,5-dihydro-2,5-bis(3,4-methylenedioxyphenyl)- 3-furancarboxylate. | 1989 | Acta Crystallogr C | pmid:2604943 |
Peterson JR et al. | Platelet activating factor antagonist design: structure of methyl trans-5-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydro-2-oxo-4- furancarboxylate. | 1989 | Acta Crystallogr C | pmid:2610971 |
Peterson JR et al. | Platelet activating factor antagonist design. 2. X-ray structure of dimethyl 2,3,4,5-tetrahydro-5 beta-(3,4-methylenedioxyphenyl)-2-oxo-3 beta-(3,4,5-trimethoxybenzoyl)-3 alpha,4 alpha-furandicarboxylate. | 1989 | Acta Crystallogr C | pmid:2610989 |
Stensland JB et al. | Platelet activating factor antagonists. Structure of N,N'-bis(3,4,5-trimethoxybenzoyl)-2-piperazinylmethyl 2,2-dimethylpropanoate. | 1991 | Acta Crystallogr C | pmid:1930821 |
Juhlin L and Pihl-Lundin I | Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects. | 1992 | Acta Derm. Venereol. | pmid:1357858 |
Juhlin L and Rihoux JP | Effect of cetirizine on cutaneous reactions to PAF, kallikrein and serum in patients with chronic urticaria. | 1990 | Acta Derm. Venereol. | pmid:1969202 |
Fjellner B and Hägermark O | Experimental pruritus evoked by platelet activating factor (PAF-acether) in human skin. | 1985 | Acta Derm. Venereol. | pmid:2416164 |
Abramovici Y et al. | Control of the proliferation and differentiation of GEJ under platelet aggregating factor treatment. | 1987 | Acta Endocrinol Suppl (Copenh) | pmid:3475908 |
Plachot M | Markers for establishing the adequacy of embryonal development in assisted conception. | 1993 Sep-Oct | Acta Eur. Fertil. | pmid:7985464 |
Aderka D et al. | Morphological platelet anomalies in thrombotic thrombocytopenic purpura. | 1982 | Acta Haematol. | pmid:6801893 |
Bussolino F et al. | Platelet-activating factor--a powerful lipid autacoid possibly involved in microangiopathy. | 1986 | Acta Haematol. | pmid:3019063 |